Terms: = Thyroid cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2 AND Prognosis
2 results:

---

1. Characterization of the genomic alterations in poorly differentiated thyroid cancer.
Lee Y; Moon S; Seok JY; Lee JH; Nam S; Chung YS
Sci Rep; 2023 Nov; 13(1):19154. PubMed ID: 37932340
[TBL]

[Abstract]

[Full Text] [Related]  

2. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
[TBL]

[Abstract]

[Full Text] [Related]  

---

of 1.